The developer of a new antifungal agent designed as an inhaled therapy for invasive pulmonary aspergillosis, has received $92 million in new capital. UK-based Pulmocide Ltd will use the Series C financing to carry out a Phase 3 registration trial for the drug PC945, which is a triazole antifungal agent.
